Inhibition of SUMOylation enhances responses to irreversible electroporation in pancreatic cancer
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Surgery"
DOI: 10.1093/bjs/znab202.027
Abstract: The revolutionary results of immunotherapy have not yet translated to pancreatic cancer (PC). Irreversible electroporation (IRE) is a non-thermal ablative therapy that can generate tumor-specific immune responses, yet not sufficient to eradicate distant metastatic disease.… read more here.
Keywords: cd8 cells; ire; tak 981; irreversible electroporation ... See more keywords
A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models
Sign Up to like & getrecommendations! Published in 2021 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.aba7791
Abstract: Description TAK-981, a first-in-class small-molecule SUMOylation inhibitor, activates type I interferon signaling to promote antitumor immune responses in mice. Stopping SUMOylation to improve immune responses SUMOylation, a reversible posttranslational modification, can suppress type I interferon… read more here.
Keywords: sumoylation; tak 981; small molecule; immune responses ... See more keywords
Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model
Sign Up to like & getrecommendations! Published in 2022 at "Gut"
DOI: 10.1136/gutjnl-2021-324834
Abstract: Objective Pancreatic ductal adenocarcinoma (PDAC) has the characteristics of high-density desmoplastic stroma, a distinctive immunosuppressive microenvironment and is profoundly resistant to all forms of chemotherapy and immunotherapy, leading to a 5-year survival rate of 9%.… read more here.
Keywords: cell; cycle progression; tak 981; cell cycle ... See more keywords
Abstract LB-319: Establishment of automated multiplex immunofluorescence T-cell panel for baseline screening of syngeneic mouse models and evaluation of T-cell infiltration in A20 syngeneic tumors treated with TAK-981, a first-in-class SUMO inhibitor
Sign Up to like & getrecommendations! Published in 2019 at "Tumor Biology"
DOI: 10.1158/1538-7445.am2019-lb-319
Abstract: Mouse syngeneic tumor models play a crucial role in the translationally oriented process of assessing the preclinical activity and mechanism of action of emerging novel immunotherapies and immunotherapy combinations. Recent advancements in fluorescent multiplex technology… read more here.
Keywords: sumo inhibitor; tak 981; syngeneic; mouse ... See more keywords
SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021014267
Abstract: SUMOylation is a reversible post-translational modification that has been implicated in the regulation of various cellular processes including inflammatory responses and expression of Type I interferons (IFN1). In this report, we have explored the activity… read more here.
Keywords: cell; tak 981; activity; sumoylation inhibitor ... See more keywords
TAK-981, a SUMOylation inhibitor, suppresses AML growth immune-independently.
Sign Up to like & getrecommendations! Published in 2023 at "Blood advances"
DOI: 10.1182/bloodadvances.2022007956
Abstract: Acute myeloid leukemia (AML) generally has an unsatisfactory prognosis despite recent introduction of new regimens including targeted agents and antibodies. To find a new druggable pathway, we performed integrated bioinformatic pathway screening on large OHSU… read more here.
Keywords: aml; sumoylation; tak 981; sumoylation inhibitor ... See more keywords